SLC5A2 and chronic kidney disease: Based on the established benefits of GLP1-RA and SGLT2-i in chronic kidney disease and the promising data about their efficacy and safety after kidney transplantation, the prescription of these novel anti-diabetic agents is expected to grow among kidney transplant recipients.